Therapeutic and diagnostic methods for cancer

A method for (i) determining whether a patient suffering from a bladder cancer is likely to respond to treatment comprising atezolizumab or (ii) predicting responsiveness of a patient suffering from a bladder cancer to treatment comprising atezolizumab, the method comprising:

• determining the expression level of PD-L1 in tumor-infiltrating immune cells in a tumor sample obtained from the patient,
• wherein a detectable expression level of PD-L1 in tumor-infiltrating immune cells that comprise about 5% or more of the tumor sample indicates that the patient is likely to respond to treatment comprising atezolizumab, wherein the tumor sample obtained from the patient has been determined to be a luminal cluster II subtype tumor;
• and administering to the patient a therapeutically effective amount of atezolizumab.

A method for selecting a therapy for a patient suffering from a bladder cancer, the method comprising:

• determining the expression level of PD-L1 in tumor-infiltrating immune cells in a tumor sample obtained from the patient,
• selecting a therapy comprising atezolizumab for the patient based on a detectable expression level of PD-L1 in tumor-infiltrating immune cells that comprise about 5% or more of the tumor sample, wherein a detectable expression level of PD-L1 in tumor-infiltrating immune cells that comprise about 5% or more of the tumor sample indicates that the patient is likely to respond to treatment comprising atezolizumab, wherein the tumor sample obtained from the patient has been determined to be a TCGA luminal cluster II subtype tumor;
• and administering to the patient a therapeutically effective amount of atezolizumab.